Tags

Type your tag names separated by a space and hit enter

CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Nat Rev Neurol. 2018 06; 14(6):338-350.NR

Abstract

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these drugs come into clinical use, we provide an overview of knowledge that has led to successful development of these drugs. We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine.

Authors+Show Affiliations

Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden. lars.edvinsson@med.lu.se. Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet, Glostrup, Denmark. lars.edvinsson@med.lu.se.Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet, Glostrup, Denmark.Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden. Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet, Glostrup, Denmark.Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden. Department of Pharmacology, School of Medicine, University of California at Irvine, Irvine, CA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29691490

Citation

Edvinsson, Lars, et al. "CGRP as the Target of New Migraine Therapies - Successful Translation From Bench to Clinic." Nature Reviews. Neurology, vol. 14, no. 6, 2018, pp. 338-350.
Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350.
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nature Reviews. Neurology, 14(6), 338-350. https://doi.org/10.1038/s41582-018-0003-1
Edvinsson L, et al. CGRP as the Target of New Migraine Therapies - Successful Translation From Bench to Clinic. Nat Rev Neurol. 2018;14(6):338-350. PubMed PMID: 29691490.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CGRP as the target of new migraine therapies - successful translation from bench to clinic. AU - Edvinsson,Lars, AU - Haanes,Kristian Agmund, AU - Warfvinge,Karin, AU - Krause,Diana N, PY - 2018/4/25/pubmed PY - 2019/8/29/medline PY - 2018/4/26/entrez SP - 338 EP - 350 JF - Nature reviews. Neurology JO - Nat Rev Neurol VL - 14 IS - 6 N2 - Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these drugs come into clinical use, we provide an overview of knowledge that has led to successful development of these drugs. We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine. SN - 1759-4766 UR - https://www.unboundmedicine.com/medline/citation/29691490/CGRP_as_the_target_of_new_migraine_therapies___successful_translation_from_bench_to_clinic_ L2 - https://doi.org/10.1038/s41582-018-0003-1 DB - PRIME DP - Unbound Medicine ER -